International Clinical Trial: Tislelizumab conbined with docetaxel/cisplatin induction chemotherapy followed by concurrent chemoradiotherapy in non-metastatic stage T4/N3 nasopharyngeal carcinoma: a phase II, multicenter, single arm study

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114985) titled 'Tislelizumab conbined with docetaxel/cisplatin induction chemotherapy followed by concurrent chemoradiotherapy in non-metastatic stage T4/N3 nasopharyngeal carcinoma: a phase II, multicenter, single arm study' on Dec. 19, 2025.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Shanghai Proton and Heavy Ion Hospital

Condition: nasopharyngeal carcinoma

Recruitment Status: Recruiting

Phase: 2

Date of First Enrollment: 2023-05-29

Target Sample Size: Single-arm group:59;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=200237

Publ...